Information  X 
Enter a valid email address

Nuformix PLC (NFX)

  Print      Mail a friend

Wednesday 02 December, 2020

Nuformix PLC

Appointment of Non-Executive Director

RNS Number : 1967H
Nuformix PLC
02 December 2020

Nuformix plc


Appointment of Madeleine Kennedy as Non-Executive Director


Cambridge, UK - 2 December 2020:  Nuformix plc (LSE:NFX; "Nuformix", the "Company" or the "Group"), a drug re-purposing specialist, is pleased to announce that Madeleine ("Maddy") Kennedy, FCCA, will join the Board of Nuformix as a Non-Executive Director with immediate effect. Maddy will be appointed as Chair of the Audit Committee.


Maddy is currently CFO and Board Director of Concepta PLC and CFO of CFO4Growth Limited. She has previously acted as interim CFO for Ieso Digital Health Ltd and PsiOxus Therapeutics Ltd, was CFO for Lab21 Limited and Finance Director at Alliance Pharma plc, taking it through its IPO. She specialises in growing life science businesses and has more than 20 years' experience in the sector, both in public and private companies.


Dr Chris Blackwell, Executive Chairman, commented:

"It's a pleasure for us to welcome Maddy to the Board. Maddy's knowledge and experience will be extremely valuable as the Company moves forward with its near-term strategic priorities. "

Commenting on her appointment, Maddy Kennedy said:

"I am delighted to be joining the Board of Nuformix and look forward to working with the Board and the team, to achieve its strategic objectives."



No further information is required to be disclosed pursuant to LR 9.6.13R of the UK Listing Rules.

The person responsible for arranging the release of this announcement on behalf of the Company is Dr Chris Blackwell, Executive Chairman.




Nuformix plc

Dr Chris Blackwell, Executive Chairman

Fleur Wood, Investor Relations

Email: [email protected]



+44 (0)1223 627222


Novum Securities Limited

Jon Belliss / Colin Rowbury 


+44 (0)20 7399 9427


About Nuformix

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines which provide therapeutic and commercial advantages to the currently available drug form. Nuformix's model of repurposing drugs utilises many technologies but is focussed on its acknowledged expertise in the use of cocrystal technology through which the Group has developed and patented novel forms of small molecules. Its platform is not therapy-specific but instead has broad application across a wide range of indications. Using its technology, the Group is developing proprietary medicines for its own development pipeline and in partnership with pharmaceutical and biotech companies.


Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information please visit .




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t